(NASDAQ: CDXC) Chromadex's forecast annual revenue growth rate of 18.04% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 59.52%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.23%.
Chromadex's revenue in 2024 is $83,570,000.On average, 2 Wall Street analysts forecast CDXC's revenue for 2024 to be $7,289,922,622, with the lowest CDXC revenue forecast at $7,154,366,210, and the highest CDXC revenue forecast at $7,425,479,035. On average, 2 Wall Street analysts forecast CDXC's revenue for 2025 to be $8,679,375,850, with the lowest CDXC revenue forecast at $8,585,239,452, and the highest CDXC revenue forecast at $8,773,512,247.
In 2026, CDXC is forecast to generate $10,385,127,372 in revenue, with the lowest revenue forecast at $10,385,127,372 and the highest revenue forecast at $10,385,127,372.